Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10280-10292

  Falchook, Gerald S ^a   Wheler, Jennifer J ^b   Naing, Aung ^b   Jackson, Edward F ^c   Janku, Filip ^b   Hong, David ^b   Ng, Chaan S ^b   Tannir, Nizar M ^b   Lawhorn, Kristie N ^b   Huang, Mei ^b   Angelo, Laura S ^d   Vishwamitra, Deeksha ^b   Hess, Kenneth ^b   Howard, Adrienne N ^b   Parkhurst, Kristin L ^b   Amin, Hesham M ^b   Kurzrock, Razelle ^e  

^a Sarah Cannon Research Institute   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bevacizumab; Bortezomib; HIF 1 ; Phase 1; Proteasome

Indexed keywords

20S PROTEASOME; BEVACIZUMAB; BORTEZOMIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HIF1A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NASOPHARYNX CANCER; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STOMACH CANCER; THROMBOCYTOPENIA; UROGENITAL TRACT TUMOR; UTERINE CERVIX CANCER; UTERINE TUBE TUMOR; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BORONIC ACIDS; BORTEZOMIB; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; FATIGUE; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84916912453     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2163     Document Type: Article

References (50)

1. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005; 11:3514-3522.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182-1186.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23:1011-1027.
4. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994; 79:185-188.
5. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69:4-10.
6. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007; 9:1221-1235.
7. Blagosklonny M. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol. 2001; 19:257-262.
8. Blagosklonny M. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5:13-17.
9. Choi K, Bae M, Jeong J, Moon H, Kim K. Hypoxia-induced angiogenesis during carcinogenesis. Journal of Biochemistry and Molecular Biology. 2003; 36:120-127.
10. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69:11-16.
11. Lee J, Bae S, Jeong J, Kim S, Kim J. Hypoxia-inducible factor (HIF-1)a: its protein stability and biological functions. Experimental and Molecular Medicine. 2004; 36:1-12.
12. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targetting hypoxia-inducible factor-1a ? hypoxia response element ? VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research. 2000; 60:6248-6252.
13. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295:1526-1528.
14. Zhong H, DeMarzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Research. 1999; 59:5830-5835.
15. Poon E, Harris AL, Ashcroft M. Targeting the hypoxia- inducible factor (HIF) pathway in cancer. Expert Rev Mol Med. 2009; 11:e26.
16. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3:721-732.
17. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther. 2004; 3:608-611.
18. Powis G, Kirkpatrick L. Hypoxia inducible factor- 1a as a cancer drug target. Molecular Cancer Therapeutics. 2004; 3:647-654.
19. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Current Cancer Drug Targets. 2003; 3:391-405.
20. Welsh SJ, Koh MY, Powis G. The hypoxic inducible strss response as a target for cancer drug discovery. Semin Oncol. 2006; 33:486-497.
21. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25:5165-5171.
22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-2342.
23. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22:2184-2191.
24. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349:427-434.
25. Friedman HS, Prados MD, Wen PY, Mikkelsen T, SchiffD, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27:4733-4740.
26. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003; 29:3-9.
27. Ludwig J, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologica and solid malignancies. Cancer. 2005; 104:1794-1807.
28. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): A novel, first-in-class proteasominhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003; 10:361-369.
29. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer. 2007; 43:1125-1133.
30. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell International. 2005; 5:18.
31. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nature Clinical Practice Oncology. 2006; 3:374-387.
32. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui, Shiraishi, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates angiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research. 2006; 66:184-191.
33. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HIF-1alpha expression by eIF2 alpha phosphorylation- mediated translational repression. Cancer Res. 2009; 69:1836-1843.
34. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008; 111:3131-3136.
35. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008; 26:4672-4678.
36. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007; 25:4536-4541.
37. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004; 22:115-119.
38. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004; 22:3720-3725.
39. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, Chan AT, Ang KK. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012; 13:172-180.
40. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012; 69:1117-1126.
41. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med. 2007; 356:185-187.
42. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004; 10: 6290S-6295S.
43. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004; 2:89-95.
44. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012; 18:5796-5805.
45. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer. 2003; 89:8-14.
46. Hylton N. Dynamic contrast-enhanced magetic resonance imaging as an imaging biomarker. Journal of Clinical Oncology. 2006; 24:3293-3298.
47. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005; 97:172-187.
48. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast- enhanced magnetic resonance imaging. Abdom Imaging. 2005; 30:324-341.
49. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist. 2005; 10:92-103.
50. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, WeisskoffRM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. Journal of magnetic resonance imaging: JMRI. 1999; 10:223-232.